Navigation Links
Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug
Date:12/10/2009

postponements of action on Hemispherx's New Drug Application ("NDA") for Ampligen with the U.S. Food and Drug Administration ("FDA"). Specifically, the defendants portrayed the postponements as due to matters such as FDA staffing issues, while concealing that: (a) the delays were due to the Company's failure to submit a number of reports that had been requested by the FDA and which were necessary before review of the drug could be completed; (b) questions had been raised about the adequacy of data submitted with the NDA to demonstrate the drug's efficacy; and (c) the drug could not be approved unless the FDA waived its requirement for two rodent carcinogenicity studies. When Hemispherx belatedly disclosed this information on November 2, 2009, the price of Hemispherx stock dropped 22% from $1.45 per share, to close at $1.13 per share on November 3, 2009.

Then on December 1, 2009, after the market closed, Hemispherx announced that the FDA had denied the Ampligen NDA. The December 1, 2009 press release stated that the FDA concluded that the Company had not submitted "credible evidence of efficacy of Ampligen," and also lacked required testing for carcinogenicity in animals, which defendants admitted they had asked the FDA to waive. On this news, the price of Hemispherx stock dropped an additional 40% from $1.20 per share, to close at $0.71 per share on December 2, 2009.


For more information about this case, please contact:

Sherrie R. Savett, Esq.
Carole A. Broderick, Esq.
Eric Lechtzin, Esq.
BERGER & MONTAGUE, P.C.
1622 Locust Street
Philadelphia, PA 19103
Telephone: 1-888-891-2289 or 215-875-3000

Berger & Montague, founded in 1970, is a pioneer in class action litigation. The firm's approximately 70 attorneys concentrate their practice in complex litigation including securities fraud and corporate governance, antitrust, civil and human rights, consumer protection and environmental and mass torts, and have recovered several
'/>"/>

SOURCE Berger & Montague, P.C.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Frost & Sullivan: Western European Markets Confirm Undisputed Convenience and Cost Benefit of Custom Procedure Trays
2. Boston Scientific and Johnson & Johnson Announce Settlement of Patent Disputes
3. Tata Interactive Systems Partners With Bersin & Associates for Exclusive Executive Learning Forum - TLF 2009
4. Sigma-Aldrich (Nasdaq: SIAL) Announces Appointment of George Miller as Sr. Vice President, General Counsel & Secretary
5. Robbins & Myers Announces Regular Quarterly Cash Dividend
6. Delcath Systems, Inc. Appoints Dr. Krishna Kandarpa its Executive Vice President R&D and Chief Medical Officer
7. Frost & Sullivan Lauds Viatronix as European Medical Imaging Emerging Company of the Year
8. Bausch & Lomb Acquires the Commercial Assets of Italian Ophthalmic Pharmaceuticals Company Tubilux
9. Robbins & Myers Announces Fourth Quarter and Full Year 2009 Results
10. Dynatronics Appoints Douglas Sampson as Vice President of Production and Research & Development
11. Frost & Sullivan Identifies Focus on Quality Management and Adoption of a Full-service Model as Keys to the Growth of the European CRO Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... the list of stocks featured in the Analyst Blog. Every ... and events impacting stocks and the financial markets. Stocks recently ... Free Report ), Gilead (Nasdaq: GILD - Free Report ... AbbVie (NYSE: ABBV - Free Report ) and Celgene ... Zacks is promoting its ,Buy, stock recommendations. Get #1Stock ...
(Date:7/31/2014)... 2014 For the first time, cardiac surgeons, ... of the SynCardia temporary Total Artificial Heart in a ... on the Journal of Visualized Experiments website. ... on the SynCardia Total Artificial Heart implantation   ... of the SynCardia Total Artificial Heart," a July 18, ...
(Date:7/31/2014)... , July 31, 2014 Astellas has ... of corporate and employee communications in the Americas ... Winton , senior vice president, chief communications officer. ... developing and leading corporate brand initiatives and reputation ... North and South America . ...
Breaking Medicine Technology:The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 2The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 3The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 4The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 5The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 6How to Implant the SynCardia Total Artificial Heart Detailed in Peer Reviewed Paper and Matching Video 2How to Implant the SynCardia Total Artificial Heart Detailed in Peer Reviewed Paper and Matching Video 3Astellas Hires Industry Veteran Moyra Knight as Head of Corporate and Employee Communications 2
... Development of Intradigm,s ICS-283, PALO ALTO, ... developer of targeted, systemic RNA interference (RNAi),therapeutics, ... company,s,TargeTran(TM) delivery system is capable of delivering ... RNAs (siRNAs) that suppress,tumor-induced angiogenesis by silencing ...
... BiPar Sciences, Inc., a,privately held biopharmaceutical ... demonstrating that BSI-401 inhibited pancreatic cancer,cell growth ... and in combination with,oxaliplatin. BSI-401 is BiPar,s ... therapies known as PARP (poly-ADP-ribose polymerase) inhibitors. ...
Cached Medicine Technology:Intradigm Study Shows Ability of siRNAs Systemically Delivered With TargeTran(TM) System to Suppress Tumor-Induced Angiogenesis in Mice 2Intradigm Study Shows Ability of siRNAs Systemically Delivered With TargeTran(TM) System to Suppress Tumor-Induced Angiogenesis in Mice 3BiPar Announces Preclinical Data Demonstrating Anti-Tumor Activity With BSI-401, Its Second-Generation PARP Inhibitor 2
(Date:7/31/2014)... 31, 2014 LDM Global ( http://www.ldmglobal.com ... model that is simplified and predictable with fixed fees ... As a leading international provider of legal discovery management ... has become glaringly apparent that both the courts and ... budgets and the complex pricing structure that plagues the ...
(Date:7/31/2014)... 2014 (HealthDay News) -- With the World Health Organization ... Ebola outbreak has risen to 729, the U.S. ... a travel warning for,the region. The "Level 3 ... affected countries -- Guinea, Liberia and Sierra Leone -- ... is worsening in West Africa," CDC Director Dr. Tom ...
(Date:7/31/2014)... 31, 2014 Setting goals for a fitness ... on successful tips to weight loss. Fitness on the Go ... 8 years, and has worked with 6000 customers on an ... had the chance to monitor why customers start exercising with ... long they stick to their program, whether or not they ...
(Date:7/31/2014)... The VitalSleep anti snoring device is a mandibular advancement splint that ... airway to quiet snoring. , Dawn M. of Utah shared ... husband by allowing them to share the same bedroom again. ... 15 years ago and I remember nights when it was so ... to head downstairs for any relief. As the years have gone ...
(Date:7/31/2014)... York, New York (PRWEB) July 31, 2014 ... to grow, as Bernstein Liebhard LLP notes that ... that it plans to voluntarily remove its power ... to a report from Bloomberg.com, the company said ... and benefits associated with the devices remain uncertain.* ...
Breaking Medicine News(10 mins):Health News:LDM Global Announces Predictable Simple Fixed-Fee Pricing 2Health News:CDC Issues Travel Warning as West Africa Ebola Outbreak Worsens 2Health News:Fitness on the Go's Rewards Program Helps Clients Reach Their Goals 2Health News:New Snoring Mouthpiece Reviews from VitalSleep 2Health News:Uterine Morcellation Controversy Grows, as Bernstein Liebhard LLP Notes Johnson & Johnson Decision to Withdraw Power Morcellators from Market 2Health News:Uterine Morcellation Controversy Grows, as Bernstein Liebhard LLP Notes Johnson & Johnson Decision to Withdraw Power Morcellators from Market 3
... pills and capsules that show a tendency in the standard ... a faster and potentially unsafe manner in patients who have ... proven safe with testing in people. That,s the conclusion ... of ACS, Molecular Pharmaceutics , a bi-monthly journal. ...
... WASHINGTON, Sept. 23 In the year since the crash ... concerns despite rising unemployment levels and ongoing economic uncertainty, according to ... In a poll surveying 2,160 adults conducted by Harris Interactive(R) between ... the economy caused stress in their lives, down from 82 percent ...
... , PRINCETON, N.J., Sept. 23 Bringing a new ... makers of Trojan(R) Brand Condoms recently introduced Trojan 2GO(R), a new ... new product, which is designed to stand-up to purses, wallets, pockets ... food, drug and convenience retail locations, making Trojan 2GO both easy ...
... NORTHRIDGE, Calif., Sept. 23 Today, Nature Made(R) ... Greatness(TM) contest. Nature Made is the nation,s best-selling brand ... mass and club channels. The company celebrates the inherent greatness ... challenged Americans to submit their personal stories of greatness as ...
... cyber-bullying and an increase in violence among young women will ... Professor Kerry Carrington, head of Queensland University of Technology,s School ... confirm, contrary to general academic opinion, young women are fast ... will present her findings, to be revealed in her book ...
... Mich. Immune therapies have been explored as a way ... from the University of Michigan Comprehensive Cancer Center suggests that ... critical immune system cells. The study was done ... in the lab before being available for humans. But the ...
Cached Medicine News:Health News:Interview Alert: At Anniversary of Financial Meltdown, Psychologists Notice Downward Trends in Economic Stress 2Health News:Makers of Trojan(R) Brand Condoms Introduce Trojan 2GO(R), a Unique, Portable, Protective and Discreet Packaging for Condoms 2Health News:Makers of Trojan(R) Brand Condoms Introduce Trojan 2GO(R), a Unique, Portable, Protective and Discreet Packaging for Condoms 3Health News:Makers of Trojan(R) Brand Condoms Introduce Trojan 2GO(R), a Unique, Portable, Protective and Discreet Packaging for Condoms 4Health News:National 'Greatness' Contest Winners Announced 2Health News:National 'Greatness' Contest Winners Announced 3Health News:Girls' violence on the rise 2Health News:Study looks at using the immune system to reduce prostate cancer risk 2
... Tegagel hydrogel wound filler and Tegagel ... amorphous hydrogel dressings specially formulated to ... has been shown to enhance wound ... meets clinical needs for management of ...
... and Tegagel hydrogel wound filler with ... formulated to help provide a moist ... enhance wound healing. The unique, viscous, ... management of non-draining, minimally draining and ...
... a complete physician preference card system as ... for all the supply management requirements of ... system combined with a broad array of ... cart and operating suite supply and charge ...
... Esteem™ External Vacuum Therapy System restores sexual ... men. Non-invasive and low cost vacuum therapy, ... desirable outcome", makes it the ideal therapy ... Therapy System causes penile rigidity that can ...
Medicine Products: